GLP-1 regulatory timeline: approvals, retatrutide status, and why the search demand keeps rising.

Semaglutide and tirzepatide are active ingredients in FDA-approved prescription products for specific indications. Retatrutide is different: it is still an investigational Lilly compound, and any status discussion should say that plainly before discussing mechanism, phase 2 data, or phase 3 expectations.

That distinction matters for trust. A research-use catalog should not blur approved branded therapies, investigational drug development, and laboratory-use materials into the same consumer promise.

• Semaglutide: mature human evidence and multiple approved branded prescription contexts.
• Tirzepatide: FDA-approved branded prescription contexts include chronic weight management and, as of December 20, 2024, obstructive sleep apnea in adults with obesity.
• Retatrutide: phase 3 investigational program, not FDA-approved as of this article update.

The search demand is not only about weight loss. People ask about GLP-1 pathways because they now touch cardiovascular outcomes, sleep apnea, kidney and liver research questions, discontinuation effects, supply, insurance coverage, and safety monitoring.

Public figures and podcasts, including Andrew Huberman's science-audience ecosystem, have made GLP-1 language more familiar to non-specialists. That can be useful for discovery, but it should never be used as a substitute for primary studies, FDA labels, or trial registries.

The public-policy conversation is also active. Pew summarized U.S. public opinion and coverage limits in early 2026, while WHO and PAHO emphasized both the clinical importance of GLP-1 medicines and the need for access frameworks, pharmacovigilance, and caution around misuse.

For a research-use storefront, the lesson is simple: answer regulatory and safety questions directly, cite primary sources, and keep product pages separate from medical-use claims.

FDA approval of a branded prescription medicine does not validate unapproved, compounded, imported, or research-use versions for human use. It also does not create dosing guidance for a catalog product. The role of this page is to organize public evidence and status, not to recommend use.